Posted on over 1 year ago by Laurentina Kennedy The RFT Group 012302400
Dublin - 5th December 2016 – Minister for Jobs, Enterprise and Innovation Mary Mitchell O’Connor TD today announced that Takeda Pharmaceutical Company Limited (TSE: 4502) is to invest €40m in a new facility at their Grange Castle site in Dublin.
The investment by Takeda will expand their Grange Castle site’s existing footprint, with the construction of a new standalone high containment production facility dedicated to manufacturing its oncology product NINLAROTM for global markets. The investment will create approximately 40 new jobs.
This investment is supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland.
The largest pharmaceutical company in Japan and a global industry leader, Takeda first set up operations in Ireland in 1997 manufacturing products for global markets. In 2002 Takeda chose Dublin as the location for its first active pharmaceutical ingredient (API) facility outside of Japan.
Welcoming the new investment by Takeda, Minister Mitchell O'Connor said "The pharma industry makes a huge contribution to the Irish economy in terms of jobs and exports, and is one of the fastest growing sectors. Takeda's decision to manufacture their new cancer treatment in Ireland is a great win and vote of confidence in Ireland and it builds on our ongoing expansion of the sector here. I'm delighted that this investment will bring a further 40 jobs to the company's existing Clondalkin facility".
Mr. Paul Keogh, Plant Director at Takeda Ireland Grange Castle said that the additional investment in Ireland demonstrates the confidence and commitment Takeda has in its Irish operation. “We are delighted that Takeda has chosen Ireland for this investment and proud that we have been entrusted with the responsibility to produce and deliver this very important treatment for cancer patients worldwide. We have a great team here in Ireland and are committed to continuing to put patients first through the timely manufacture and supply of high quality products from our site”.
We are delighted that Takeda has chosen Ireland for this investment and proud that we have been entrusted with the responsibility to produce and deliver this very important treatment for cancer patients worldwide. We have a great team here in Ireland and are committed to continuing to put patients first through the timely manufacture and supply of high quality products from our site.Paul Keogh, Plant Director at Takeda Ireland Grange Castle
Commenting on the investment Martin Shanahan, CEO IDA Ireland said “Ireland is a globally recognised centre of excellence in Life sciences due to the country’s strong regulatory track record and talent availability. Today’s investment by Takeda demonstrates their continued commitment to Ireland. I wish the Takeda team every success as they continue to grow their operations in Ireland.”
About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com/news.
Additional information about Takeda is available through its corporate website, www.takeda.com, and additional information about Takeda Oncology, the brand for the global oncology business unit of Takeda Pharmaceutical Company Limited, is available through its website, www.takedaoncology.com.
About NINLAROTM (Ixazomib) capsules
NINLAROTM (ixazomib) is an oral proteasome inhibitor which is also being studied across the continuum of multiple myeloma treatment settings as well as systemic light-chain (AL) amyloidosis. It was the first oral proteasome inhibitor to enter Phase 3 clinical trials and to receive approval. NINLARO was approved by the U.S. Food and Drug Administration (FDA) in November 2015 following a priority review. In the U.S., NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.